AI Therapeutics Announces the Acquisition of Novel Cancer Drug Candidate EC-8042 (AIT-102)
25 avr. 2022 10h30 HE
|
AI Therapeutics, Inc.
GUILFORD, Conn., April 25, 2022 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., an AI driven clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, today announced the...
AI Therapeutics Appoints Brigette Roberts, M.D., as Chief Executive Officer
16 févr. 2022 10h38 HE
|
AI Therapeutics, Inc.
GUILFORD, Conn., Feb. 16, 2022 (GLOBE NEWSWIRE) -- AI Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for rare diseases, today announced the appointment of...